Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension
- 1 April 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 51 (4), 862-866
- https://doi.org/10.1161/hypertensionaha.107.103127
Abstract
The thrombotic microangiopathy observed in malignant hypertension is similar to that of thrombotic thrombocytopenic purpura, which is associated with a deficiency of ADAMTS13, a von Willebrand factor (VWF)–cleaving protease that cleaves large prothrombogenic multimers. We hypothesized that ADAMTS13 is deficient in malignant hypertension and that the severity of thrombotic microangiopathy is associated with decreased ADAMTS13 activity. We included 20 patients with malignant and 20 patients with severe hypertension, and 20 matched normotensive individuals served as control subjects. VWF, active VWF, and free hemoglobin were assessed to explore predictors of ADAMTS13 activity. Patients with malignant hypertension had lower ADAMTS13 activity (80%; interquartile range: 53% to 130%) compared with control subjects (99% interquartile range: 82% to 129%; P P =0.14). ADAMTS13 activity negatively correlated with lactic dehydrogenase levels after logarithmic transformation ( r =−0.65; P r =0.34; P =0.04) and the presence of schistocytes ( r =−0.37; P =0.02). Apart from the association with thrombotic microangiopathy, ADAMTS13 was inversely associated with creatinine ( r =−0.42; P =0.008). Increasing levels of VWF were associated with a decrease in ADAMTS13 activity ( r =−0.34; P =0.03). There was no significant association between ADAMTS13 activity and other parameters, including blood pressure. In conclusion, ADAMTS13 is decreased in malignant hypertension and associated with the severity of thrombotic microangiopathy, likely because of the release of VWF after endothelium stimulation. A severe deficiency could not be demonstrated. More studies are needed to identify the role of ADAMTS13 in the thrombotic microangiopathy and ischemic complications of malignant hypertension.Keywords
This publication has 19 references indexed in Scilit:
- Severe secondary deficiency of von Willebrand factor–cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failureBlood, 2006
- A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2BBlood, 2005
- FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assayBritish Journal of Haematology, 2005
- Microangiopathic Hemolysis and Renal Failure in Malignant HypertensionHypertension, 2005
- Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobinBlood, 2005
- Changes in von Willebrand factor–cleaving protease (ADAMTS13) activity after infusion of desmopressinBlood, 2003
- ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditionsBlood, 2002
- Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 1998
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 1998
- Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.JCI Insight, 1986